Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome profile of OVCAR3 cells treated with DMSO or THZ531 (200nM) for 6hr

ABSTRACT: Transcriptome profile of OVCAR3 cells treated with DMSO or THZ531 (200nM) for 6hr

PROVIDER: PRJNA922206 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23029313_1.fastq.gz	Fastqsanger.gz
	SRR23029313_2.fastq.gz	Fastqsanger.gz
	SRR23029314_1.fastq.gz	Fastqsanger.gz
	SRR23029314_2.fastq.gz	Fastqsanger.gz
	SRR23029315_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Transcriptome profile of OVCAR3 cells treated with DMSO or THZ531 (200nM) for 6hr

Project description:Transcription-associated cyclin-dependent kinases (CDKs) regulate the transcription cycle through sequential phosphorylation of the RNA polymerase II (RNAPII). We report that dual inhibition of the highly homologous CDK12 and CDK13 impairs splicing of a subset of promoter-proximal introns characterized by weak 3’ splice sites located at larger distance from the branchpoint. Nascent transcript analysis indicated that these introns are selectively retained upon pharmacologic inhibition of CDK12/13 with respect to downstream introns of the same pre-mRNAs. Retention of these introns was also triggered by Pladienolide B (PdB), an inhibitor of the U2 snRNP factor SF3B1 that recognizes the branchpoint. CDK12/13 activity promotes the interaction of SF3B1 with the RNAPII phosphorylated on serine 2 and disruption of this interaction by treatment with the CDK12/13 inhibitor THZ531 impairs the association of SF3B1 with the chromatin and its recruitment to the 3’ splice site of these introns. Furthermore, by using suboptimal doses of THZ531 and PdB, we describe a synergic effect of these inhibitors on intron retention, cell cycle progression and cancer cell survival. These findings uncover a mechanism by which CDK12/13 couple RNA transcription and processing and suggest that combined inhibition of these kinases and the spliceosome represents an exploitable anticancer approach.

2023-03-29 | GSE222493 | GEO

PolyA-sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:We performed RNA-seq analsysis of polA transcripts in IMR-32 cells treated with THZ531 for 2 and 6h and DMSO as a control

2019-03-26 | GSE113312 | GEO

Global gene expression analysis in DMSO and THZ531 treated IMR32 and Kelly cells

Project description:We performed gene expression profiling by Affymetrix primeview array in both DMSO and THZ531 treated cells.

2019-03-26 | GSE113311 | GEO

Nascent RNA sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:We performed RNA-seq analsysis of nascent transcripts obtained by 4sU labeling in IMR-32 cells treated with THZ531 for 30min and 2h and DMSO as a control

2019-03-26 | GSE113313 | GEO

PolyA-sequencing in Kelly and Kelly E9R neuroblastoma cells treated with THZ531 or DMSO

Project description:We performed RNA-seq analsysis of polA transcripts in Kelly and Kelly E9 resistant (E9R) cells treated with THZ531 for 6h and DMSO as a control

2019-03-26 | GSE122303 | GEO

PolyA-sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:PolyA-sequencing in IMR-32 cells treated with THZ531 or DMSO

| PRJNA450797 | ENA

Gene expression profiling in melanoma cell lines treated with THZ531 or DMSO

Project description:RNA seq of BRAF-mutated melanoma cell lines (A375 and Colo829) treated with CDK12 inhibitor (THZ531, 500nM) for 6 hours

2022-10-06 | GSE184734 | GEO

Gene expression profiling in melanoma cell lines treated with THZ531 or DMSO

Project description:Gene expression profiling in melanoma cell lines treated with THZ531 or DMSO

| PRJNA766024 | ENA

Nascent RNA sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:Nascent RNA sequencing in IMR-32 cells treated with THZ531 or DMSO